These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17148749)
1. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Sloth B; Holst JJ; Flint A; Gregersen NT; Astrup A Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1062-8. PubMed ID: 17148749 [TBL] [Abstract][Full Text] [Related]
2. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Sloth B; Davidsen L; Holst JJ; Flint A; Astrup A Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E604-9. PubMed ID: 17566112 [TBL] [Abstract][Full Text] [Related]
3. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885 [TBL] [Abstract][Full Text] [Related]
4. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Witte AB; Grybäck P; Holst JJ; Hilsted L; Hellström PM; Jacobsson H; Schmidt PT Regul Pept; 2009 Nov; 158(1-3):57-62. PubMed ID: 19651163 [TBL] [Abstract][Full Text] [Related]
5. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186 [TBL] [Abstract][Full Text] [Related]
6. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. van den Hoek AM; Heijboer AC; Voshol PJ; Havekes LM; Romijn JA; Corssmit EP; Pijl H Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E238-45. PubMed ID: 16940471 [TBL] [Abstract][Full Text] [Related]
7. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Chelikani PK; Haver AC; Reidelberger RD Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R39-46. PubMed ID: 17428898 [TBL] [Abstract][Full Text] [Related]
8. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917 [TBL] [Abstract][Full Text] [Related]
9. Effects of exercise on gut peptides, energy intake and appetite. Martins C; Morgan LM; Bloom SR; Robertson MD J Endocrinol; 2007 May; 193(2):251-8. PubMed ID: 17470516 [TBL] [Abstract][Full Text] [Related]
10. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. van den Hoek AM; Heijboer AC; Corssmit EP; Voshol PJ; Romijn JA; Havekes LM; Pijl H Diabetes; 2004 Aug; 53(8):1949-52. PubMed ID: 15277371 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of food intake in obese subjects by peptide YY3-36. Batterham RL; Cohen MA; Ellis SM; Le Roux CW; Withers DJ; Frost GS; Ghatei MA; Bloom SR N Engl J Med; 2003 Sep; 349(10):941-8. PubMed ID: 12954742 [TBL] [Abstract][Full Text] [Related]
12. Lean and obese dietary phenotypes: differences in energy and substrate metabolism and appetite. Clamp L; Hehir AP; Lambert EV; Beglinger C; Goedecke JH Br J Nutr; 2015 Nov; 114(10):1724-33. PubMed ID: 26382929 [TBL] [Abstract][Full Text] [Related]
13. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Doucet E; Laviolette M; Imbeault P; Strychar I; Rabasa-Lhoret R; Prud'homme D Metabolism; 2008 Oct; 57(10):1458-64. PubMed ID: 18803953 [TBL] [Abstract][Full Text] [Related]
14. Effects of whole grain rye, with and without resistant starch type 2 supplementation, on glucose tolerance, gut hormones, inflammation and appetite regulation in an 11-14.5 hour perspective; a randomized controlled study in healthy subjects. Sandberg JC; Björck IME; Nilsson AC Nutr J; 2017 Apr; 16(1):25. PubMed ID: 28431559 [TBL] [Abstract][Full Text] [Related]
15. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815 [TBL] [Abstract][Full Text] [Related]
16. Short-term aerobic exercise training increases postprandial pancreatic polypeptide but not peptide YY concentrations in obese individuals. Kanaley JA; Heden TD; Liu Y; Whaley-Connell AT; Chockalingam A; Dellsperger KC; Fairchild TJ Int J Obes (Lond); 2014 Feb; 38(2):266-71. PubMed ID: 23736355 [TBL] [Abstract][Full Text] [Related]
17. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Asmar M; Tangaa W; Madsbad S; Hare K; Astrup A; Flint A; Bülow J; Holst JJ Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E614-21. PubMed ID: 19996386 [TBL] [Abstract][Full Text] [Related]
18. Cholinergic regulation of ghrelin and peptide YY release may be impaired in obesity. Maier C; Riedl M; Vila G; Nowotny P; Wolzt M; Clodi M; Ludvik B; Luger A Diabetes; 2008 Sep; 57(9):2332-40. PubMed ID: 18567824 [TBL] [Abstract][Full Text] [Related]
19. Effects of oral fat perception by modified sham feeding on energy expenditure, hormones and appetite profile in the postprandial state. Smeets AJ; Lejeune MP; Westerterp-Plantenga MS Br J Nutr; 2009 May; 101(9):1360-8. PubMed ID: 18814804 [TBL] [Abstract][Full Text] [Related]
20. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]